ARID1B and cancer: Van der Sluijs et al. (2019) reported 143 CSS/NDDs patients with ARID1B variants and only found one boy with malignancy (van der Sluijs et al., 2019). In our compilation and report of ARID2 and ARID1B variants, all patients with truncated variants did not have cancers. It suggested that pathogenic germline variants in ARID2 and ARID1B did not increase the cancer risk, which should be verified by more investigations.